



Time (SGT)	Day 1 Wednesday, September 8	Day 2 Thursday, September 9	Day 3 Friday, September 10	Day 4 Saturday, September 11	Day 5 Sunday, September 12	Day 6 Monday, September 13	Day 7 Tuesday, September 14	Time (SGT)
19:00								19:00
19:15								19:15
19:30								19:30
19:45								19:45
20:00	19:45 - 20:45 MTE03: Targeted Therapies and/or Immunotherapy	19:45 - 20:45 MTE02: Screening, Incidental Nodules, and Adjuvant Therapy for Early-Stage Lung Cancer	19:45 - 20:45 IS08: Industry Symposium	19:45 - 20:45 IS09: Industry Symposium	19:45 - 20:45 IS10: Satellite CME Symposium by Research to Practice			20:00
20:15								20:15
20:30								20:30
20:45								20:45
21:00	21:00 - 22:00 Plenary 1: Opening Plenary Access and Disparities	20:30 - 22:00 Plenary 2: Presidential Symposium	21:00 - 22:00 JIES01: Joint IASLC - ESTRO Session: Advances in Radiotherapy for Lung Cancer	21:30 - 22:05 ES01: Proactive Tobacco and Cancer Control Track: Risk Reduction and Tobacco Control				21:00
21:15								21:15
21:30								21:30
21:45								21:45
22:00								22:00
22:15	22:15 - 23:15 MA01: Multimodality Management of Advanced Lung Cancer Track: Multimodality Management of Advanced Lung Cancer	22:15 - 23:15 OA01: The Impact of COVID-19 on Patients with Lung Cancer Track: Management of Lung Cancer in the Era of COVID-19	22:15 - 23:15 MA05: Using Real World and Patient Reported Data to Identify Gaps and Needs... Track: Patient Advocacy	22:15 - 23:15 OA06: Prognosis and Staging Track: Staging/Pulmonary Medicine	22:15 - 23:15 OA07: What's on the Horizon for SCLC? Track: SCLC/NET	22:00 - 23:30 WS01: Middle East/North Africa Workshop - Presenting the Current Status and Future of Lung Cancer Detection and Treatment in the Region		22:15
22:30	22:15 - 23:15 MA02: RET and Novel Combinations of Osimertinib Track: Novel Therapeutics and Targeted Therapies	22:15 - 23:15 OA02: Contemporary Approaches to Supportive Care Track: Palliative and Supportive Care	22:15 - 23:15 MA06: Differentiating Outcomes and Impact in Unresectable NSCLC Track: Locally Advanced Non-Small Cell Lung Cancer	22:15 - 23:15 OA08: Moving Beyond New Drugs: What Else Matters? Track: Health Services Research/Health Economics	22:15 - 23:15 OA09: Expanding Immunotherapy Options for Non-small Cell Lung Cancers Track: Immunotherapy (Phase I/II Trials)			22:30
22:45								22:45
23:00								23:00
23:15								23:15
23:30	23:30 - 00:30 MA02: RET and Novel Combinations of Osimertinib Track: Novel Therapeutics and Targeted Therapies	23:30 - 00:30 OA03: Novel Approaches to Cessation in Cancer Care Track: Risk Reduction and Tobacco Control	23:30 - 00:30 MA06: Differentiating Outcomes and Impact in Unresectable NSCLC Track: Locally Advanced Non-Small Cell Lung Cancer	23:30 - 00:30 OA08: Moving Beyond New Drugs: What Else Matters? Track: Health Services Research/Health Economics	23:30 - 00:30 OA09: Expanding Immunotherapy Options for Non-small Cell Lung Cancers Track: Immunotherapy (Phase I/II Trials)			23:30
23:45								23:45
00:00								00:00
00:15								00:15
00:30								00:30
00:45	00:45 - 1:45 MA03: Biomarkers for Immunotherapy: Are All Relevant? Track: Immunobiology and Novel Immunotherapeutics (Phase I and Translational)	00:45 - 1:45 MA04: Current Status and Future Prospects of Pleural Mesothelioma and Thymoma and Other Thoracic Malignancies Control	00:45 - 1:45 MA07: Liquid Biopsy Applications for Immuno-oncology, Targeted Therapies, and Early Stage NSCLC Track: Liquid Biopsy and Other Non-Invasive Diagnostic Modalities	00:45 - 1:45 OA10: Improving Care for People with Lung Cancer: Biomarker Testing Access, ... Track: Patient Advocacy	00:45 - 1:45 OA11: Early Stage NSCLC Track: Early Stage/Localized Disease/Abolative Therapies			00:45
1:00								1:00
1:15								1:15
1:30								1:30
1:45								1:45
2:00	2:00 - 3:00 IS01: Industry Symposium	2:00 - 3:00 IS02: Satellite CME Symposium by Med Learning Group	2:00 - 3:00 MA08: Driver Mutations and Immune Profiles in Early Stage NSCLC Track: Early Stage/Localized Disease/Abolative Therapies	2:00 - 3:00 OA12: Understanding and Augmenting Responses to Immunotherapy for Thoracic Malignancies Track: Tumor Biology and Systems Biology: Basic and Translational Science				2:00
2:15								2:15
2:30								2:30
2:45								2:45
3:00								3:00
3:15								3:15
3:30								3:30
3:45								3:45
4:00								4:00
4:15								4:15
4:30								4:30
4:45								4:45
5:00								5:00
5:15								5:15
5:30								5:30
5:45								5:45
6:00								6:00
6:15								6:15
6:30								6:30
6:45								6:45
7:00								7:00
7:15								7:15
7:30								7:30
7:45								7:45
8:00								8:00
8:15								8:15
8:30								8:30
8:45								8:45
9:00								9:00
9:15								9:15
9:30								9:30
9:45								9:45
10:00								10:00
10:15								10:15
10:30								10:30
10:45								10:45
11:00								11:00
11:15								11:15
11:30								11:30
11:45								11:45
12:00								12:00
12:15								12:15
12:30								12:30
12:45								12:45
13:00								13:00
13:15								13:15
13:30								13:30
13:45								13:45
14:00								14:00

LEGEND: BEDG: Brain Exchange Discussion Groups MA: Mini Oral Abstract Sessions OA: Oral Abstract Sessions WS: Workshop IASLC CME Accredited Full Length Presentations Available Only On Demand (Release Date: September 1). Live Sessions Will Include Summaries and Extended Q&A Time. ES: Educational Sessions MTE: Meet the Expert Sessions PL: Plenary Sessions CME Accredited by Other Provider With Live Q&A For Web CME accreditation details please see page 2 for more details

